5 Key Takeaways

• 1

  Researchers at Merck developed a self-driving bioprocessing platform that optimizes monoclonal antibody production using machine learning.

• 2

  The platform autonomously designs and adapts perfusion cell culture experiments in real time, enhancing decision-making during cultivation.

• 3

  It integrates Bayesian experimental design with a cognitive digital twin, allowing continuous learning and real-time adjustments.

• 4

  During a 27-day monoclonal antibody production run, the system autonomously operated for 20 days, meeting performance targets.

• 5

  This innovative approach reduces the need for manual intervention and could shorten development timelines in biopharmaceutical production.